6634 Stock Overview
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sinew Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$57.50 |
| 52 Week High | NT$85.50 |
| 52 Week Low | NT$56.10 |
| Beta | 0.88 |
| 1 Month Change | -14.05% |
| 3 Month Change | -15.57% |
| 1 Year Change | -31.71% |
| 3 Year Change | -36.32% |
| 5 Year Change | 96.85% |
| Change since IPO | 15.46% |
Recent News & Updates
Shareholder Returns
| 6634 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.5% | -0.05% | 1.3% |
| 1Y | -31.7% | 4.9% | 29.2% |
Return vs Industry: 6634 underperformed the TW Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: 6634 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 6634 volatility | |
|---|---|
| 6634 Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6634 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6634's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 52 | Kaimin Chu | www.sinewpharma.com |
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States.
Sinew Pharma Inc. Fundamentals Summary
| 6634 fundamental statistics | |
|---|---|
| Market cap | NT$4.09b |
| Earnings (TTM) | -NT$170.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-23.9x
P/E RatioIs 6634 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6634 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$170.92m |
| Earnings | -NT$170.92m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6634 perform over the long term?
See historical performance and comparison